email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2641-1725

LOJ Medical Sciences

Research Article(ISSN: 2641-1725)

Docking Study of New Ortho-Phenylenediamine Derivatives as COVID-19 Protease Inhibitors Volume 5 - Issue 2

Abdul M Gbaj1*, Nisreen H Meiqal1, Inass A Sadawe1, Salah M Bensaber1, Abdulathim A A Alshoushan2, Massaud Salem Maamar3 and Anton Hermann4

  • 1Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya
  • 2Food and Drug Control Centre (LFDA), Tripoli, Libya
  • 3Department of Zoology, Faculty of Science, Tripoli University, Libya
  • 4Department of Biosciences, University of Salzburg, Salzburg, Austria

Received: March 29, 2020;   Published: June 16, 2020

*Corresponding author: Abdul M Gbaj, Associate Professor of Genetics and Biochemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya

DOI: 10.32474/LOJMS.2020.05.000207

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF


A series of new ortho-phenylenediamine derivatives were designed. The crystal structure of the main protease monomer was used as a target protein for molecular docking of ortho- phenylenediamine derivatives and a protein-ligand interaction analysis was performed using Auto Dock 4.2 software. Based on the docking score and after additional three-dimensional similarity analysis, NHM7 [(10,10’-((1E,1’E)-(1,2-phenylenebis(azanylylidene))bis(methanylylidene))bis(anthracen-9(8aH)-one)] had the highest binding energy. The calculated binding energy of ortho- phenylenediamine indicated effective binding of the proposed inhibitors to COVID-19 proteinase.

Keywords: Coronavirus; severe acute respiratory syndrome; covid-19 protease inhibitors; lopinavir; n3 inhibitor; molecular docking

Abstract| Introduction| Materials and Methods| Results and Discussion| Conclusion| Acknowledgement| References|